Drugs / MT-5625
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03507738 | Jul 2018 → Jun 2019 | — | Tanabe Pharma Corporation | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MT-5625 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03507738 ↗ |
| Route | Intramuscular | “Intramuscular injection” NCT03507738 ↗ |